Full Press Release Details
ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT
TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIIONS (SI 2019/310) ("UK MAR").
of options -PDMR dealing
March 15, 2023 - OKYO Pharma Limited (Nasdaq: OKYO; LSE: OKYO) ("OKYO" or the "Company"), an ophthalmology-focused
bio-pharmaceutical company which is developing OK-101 to treat dry eye disease ("DED") to address the significant unmet need
in this multi-billion-dollar market, today announces that the board of directors of the Company (the "Board" or "Directors"),
acting on a recommendation of the Remuneration Committee has awarded the following options (each to acquire one new ordinary share of
no par value) ("Options") to directors and persons discharging managerial responsibility:
| Gary S. Jacob | Chief Executive Officer | 5,500,000 Options |
| Keeren Shah | Chief Financial Officer | 6,550,000 Options |
| Dr. Raj Patil | Chief Scientific Officer | 15,500,000 Options |
| Willy Simon | Non-executive director | 400,000 Options |
| John Brancaccio | Non-executive director | 1,000,000 Options |
| Bernard Denoyer | Non-executive director | 200,000 Options |
exercise price for all options is 0.025 per share. The options all vest in 4 equal tranches over 4 years, with the first tranche
vesting on 14 March 2024, and all options have a life of ten years.
of the Company's ADS should note that for the purposes of comparison of the quantum of the awards, each ADS held represents 65
information set out below is provided in accordance with Article 19(3) of UK MAR:
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | PDMRs: |
| Gary S. Jacob | Chief Executive Officer | ||
| Keeren Shah | Chief Financial Officer | ||
| Dr. Raj Patil | Chief Scientific Officer | ||
| Willy Simon | Non-executive director | ||
| John Brancaccio | Non-executive director | ||
| Bernard Denoyer | Non-executive director |
| 2 | Reason for the notification | |
| a) | Position/status | See 1a) above |
| b) | Initial notification /Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | OKYO Pharma Limited |
| b) | LEI | 213800VVN5CB56Y15A05 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a) | Description of the financial instrument, type of instrument | Ordinary Shares of no par value |
| b) | Identification code | ISIN for OKYO Pharma Limited: GG00BD3FV870 |
| c) | Nature of the transaction | Grant of options |
| d) | Price(s) and volume(s) | Price: 0.025 per share Volumes: |
| Gary S. Jacob | 5,500,000 | ||
| Keeren Shah | 6,550,000 | ||
| Dr. Raj Patil Willy Simon John Brancaccio Bernard Denoyer | 15,500,000 400,000 1,000,000 200,000 |
| e) | Aggregated information - Aggregated volume - Price | n/a |
| f) | Date of the transaction | 14 March 2023 |
| g) | Place of the transaction | Outside of a trading venue |
the purposes of UK MAR, the person who arranged the release of this information is Gary S. Jacob, Chief Executive Officer of OKYO.
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | +44 (0)20 7495 2379 | ||
| Investor Relations | Paul Spencer | +44 (0)20 7495 2379 | ||
| Broker | Robert Emmet, Optiva Securities Limited | +44 (0)20 3981 4173 |
is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of
the eye responsible for the inflammatory response. OK-101 has been shown to produce anti-inflammatory and neuropathic pain-reducing activities
in mouse models of DED and corneal neuropathic pain, respectively, and is designed to combat washout through the inclusion of the lipid
anchor' contained in the drug molecule to enhance the residence time of OK-101 within the ocular environment.
Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on NASDAQ and on the standard segment of the
Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange
plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain. For
further information, please visit www.okyopharma.com.